

Transtema - M&A Fueled Growth Ahead

Redeye retains its positive view on Transtema following a Q1 report with underlying sales and EBITA in line with our forecasts. From Q2 and onwards, Tessta, which had a solid start to 2022, will be fully consolidated, driving sales and earnings.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Transtema - M&A Fueled Growth Ahead](#)